Log in

Enzo Biochem Stock Price, Forecast & Analysis (NYSE:ENZ)

+0.10 (+3.57 %)
(As of 11/17/2019 09:43 AM ET)
Today's Range
Now: $2.90
50-Day Range
MA: $3.31
52-Week Range
Now: $2.90
Volume63,662 shs
Average Volume61,763 shs
Market Capitalization$137.92 million
P/E RatioN/A
Dividend YieldN/A
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. Read More…

Industry, Sector and Symbol

Industry Medical laboratories



Sales & Book Value

Annual Sales$81.17 million
Book Value$1.81 per share


Net Income$2.49 million


Market Cap$137.92 million
Next Earnings Date12/9/2019 (Estimated)

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The medical research company earned $20.92 million during the quarter. Enzo Biochem had a net margin of 3.07% and a negative return on equity of 33.03%. View Enzo Biochem's Earnings History.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release their next quarterly earnings announcement on Monday, December 9th 2019. View Earnings Estimates for Enzo Biochem.

Has Enzo Biochem been receiving favorable news coverage?

Headlines about ENZ stock have trended extremely negative on Sunday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Enzo Biochem earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Enzo Biochem.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a drop in short interest in October. As of October 31st, there was short interest totalling 854,900 shares, a drop of 6.5% from the September 30th total of 913,900 shares. Based on an average daily trading volume, of 99,400 shares, the short-interest ratio is currently 8.6 days. Approximately 1.9% of the shares of the company are sold short. View Enzo Biochem's Current Options Chain.

Who are some of Enzo Biochem's key competitors?

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include Onelife Technologies (OLMM), Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Opko Health (OPK), AbbVie (ABBV), Array Biopharma (ARRY), Biocept (BIOC), EXACT Sciences (EXAS), Exelixis (EXEL) and Zynerba Pharmaceuticals (ZYNE).

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:
  • Dr. Elazar Rabbani, Co-Founder, Chairman, CEO & Sec. (Age 76)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 69)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 53)
  • Dr. Dieter Schapfel, Chief Medical Director - Enzo Clinical Labs (Age 56)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 61)

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a number of of retail and institutional investors. Top institutional investors include Strs Ohio (0.34%), Dalton Greiner Hartman Maher & Co. (0.17%) and Rhumbline Advisers (0.15%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani and Harbert Management Corp. View Institutional Ownership Trends for Enzo Biochem.

Which institutional investors are buying Enzo Biochem stock?

ENZ stock was acquired by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Strs Ohio and Rhumbline Advisers. Company insiders that have bought Enzo Biochem stock in the last two years include Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani and Harbert Management Corp. View Insider Buying and Selling for Enzo Biochem.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.90.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $137.92 million and generates $81.17 million in revenue each year. Enzo Biochem employs 460 workers across the globe.View Additional Information About Enzo Biochem.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is http://www.enzo.com/.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.

MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  352
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: How Do Mutual Funds Work?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel